dc.contributor.author | D’alessandro, Umberto | |
dc.contributor.author | Dujardin, Jean-Claude | |
dc.contributor.author | Laurent, Thierry | |
dc.contributor.author | Overmeir, Chantal Van | |
dc.contributor.author | Nyachieo, Atunga | |
dc.date.accessioned | 2013-07-11T12:11:04Z | |
dc.date.available | 2013-07-11T12:11:04Z | |
dc.date.issued | 2005 | |
dc.identifier.citation | The American Society of Tropical Medicine and Hygiene 73(1), 2005, pp. 210–213 | en |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/47447 | |
dc.description.abstract | In vivo tests for susceptibility to antimalarial drugs require molecular methods to distinguish recrudescence
from new infection. The most commonly used DNA markers (merozoite surface proteins [MSPs]) are under immune
selective pressure, which might lead to misclassification. We evaluated immunologically neutral microsatellite markers
in blood samples collected during a drug efficacy trial in Rwanda. Fifty percent of the infections classified as recrudescent
by MSP were classified as new by microsatellite markers. Reciprocally, 23.3% of infections classified as recrudescent by
microsatellite markers were identified as new by MSP. In drug efficacy studies, microsatellite markers should complement
MSP genotyping to distinguish a recrudescence from a new infection | en |
dc.language.iso | en | en |
dc.title | Plasmodium falciparum genotyping by microsatellites as a method to distinguish between recrudescent and new infections | en |
dc.type | Article | en |
local.publisher | Department of Biochemistry | en |